Greenwich LifeSciences Extends Share Lock-Up Period to September 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Globenewswire
- Lock-Up Extension: Greenwich LifeSciences has announced an extension of the lock-up period for shares held by directors, officers, and existing investors until September 30, 2026, approximately 72 months post-IPO, aimed at aligning interests with long-term investors and supporting the FLAMINGO-01 Phase III trial.
- Clinical Trial Progress: The FLAMINGO-01 trial has screened over 1,000 patients, with a current screening rate of approximately 600 patients per year, and the non-HLA-A*02 arm is fully enrolled with 250 patients receiving GLSI-100, representing a fivefold increase in treated patients compared to the Phase II trial.
- Significant Recurrence Reduction: Preliminary data indicates an approximately 80% reduction in recurrence rates in the non-HLA-A*02 arm after completing the Primary Immunization Series, trending similarly to Phase II results, highlighting GLSI-100's potential in preventing breast cancer recurrences.
- Future Flexibility in Plans: The Board retains the ability to modify lock-up and leak-out plans at any time, potentially maintaining a high percentage of locked shares while allowing a small fraction to be sold under a 10b5-1 trading plan, ensuring alignment of interests between the company and its investors.
GLSI
$20.685+Infinity%1D
Analyst Views on GLSI
Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 17.210
Low
45.00
Averages
45.00
High
45.00
Current: 17.210
Low
45.00
Averages
45.00
High
45.00
About GLSI
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
